Septhemba 2022: Ngokocwaningo olushicilelwe ku-Journal of Clinical Investigation, unjiniyela wase-University of Houston (UH) kungenzeka ukuthi uthole indlela yokuhlonza ukuthi yiziphi iziguli ze-lymphoma okungenzeka ziphendule ekwelashweni kwe-T-cell chimeric antigen receptor (CAR).
Physicians can expedite treatment and maybe save more lives if they are aware of which lymphoma patients react to CAR T-cell therapy. On the other hand, sharing light on people who react poorly and experience serious side effects can open up more possibilities for alternative treatments.
Abacwaningi bathola ukuxhumana okukhethekile phakathi kwe-T cell protein CD2 kanye ne-cancer receptor CD58 ophenyweni lwabo.
In the tumours of lymphoma patients who benefit more from Ukwelashwa kwe-CAR T-cell, the CD2 ligand CD58 is expressed at higher levels, according to study author Navin Varadarajan, PhD, MD Anderson professor of chemical and biomolecular engineering.
I-AT cell's CD2 protein iboshwe yi-CD58. Lapho i-CD58 yenza i-CD2 isebenze, iphrotheni iyashintsha ibe ingqamuzana elingashabalalisa amangqamuzana omdlavuza lapho ethintana.
According to certain recent studies, cancer can be treated by using the patient’s own biological system. One particular technique, called Ukwelashwa kwe-CAR T-cell, modifies T cells in the lab so that they will fight cancer cells once they have returned to the body. The consequences of this life-saving procedure could linger for ten years or longer.
Ukuze kwenziwe uphenyo olunzulu mayelana nokuhlobana phakathi kwe-CD58 ne-CD2, u-Varadarajan usebenzisane nethimba labacwaningi abavela eNyuvesi yaseTexas MD Anderson Cancer Center.
U-Varadarajan usebenzisane no-Sattva Neelapu (MD Anderson) ukuze angcolise amathumba esiguli ngaphambi kokwelashwa kwe-CAR T futhi ahlole ukusho kweseli esebenzisa indlela ye-TIMING (Timelapse Imaging Microscopy In Nanowell Grids) u-Varadarajan ayithuthukisa elebhu yakhe. Lobu buchwepheshe beseli elilodwa bungahlola ukuthi amaseli anyakaza, asebenze, abulale, aphile, futhi ahlanganyele kanjani.
The scientists discovered that tumours expressing higher amounts of the cancer receptor CD58 responded better to Ukwelashwa kwe-CAR T-cell based on the hundreds of interactions they saw between T cells and tumour cells using TIMING.
Varadarajan stated in the news announcement, “We found that CD2 on T cells is related with directional migration. Death and serial killing are accelerated by the interaction between CD2 on T cells and CD58 on i-lymphoma amaseli.
I-Varadarajan ihlose ukuthengisa indlela ye-TIMING. Wasungula ibhizinisi elizinze e-UH i-CellChorus. Iziguli zingase zithumele i-CellChorus amaseli azo eziqondiswe kuwo ngamunye; lawa maseli azohlolwa kusetshenziswa ukuhlolwa kwe-TIMING; le sevisi ayikafinyelelwa ochwepheshe.
Enkulumweni yabezindaba, u-Varadarajan uthe, "Sinenhlanhla enkulu yokuba ne-Technology Bridge njengendawo yethu yokufukamela e-Houston, eduze kwesikhungo sezokwelapha esiphezulu sesizwe, esikwazi ukufinyelela okuyingqayizivele ezikhungweni zezokwelapha okunzima ukuphindaphinda kwamanye amadolobha amaningi izwe.
